Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (GANX): 3 pipeline candidates · ~11 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
10.8 months
D/E 0.34 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Gain Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$75.9M
Cash
$16.6M
Quarterly Burn
$4.7M
Runway
10.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| gt-02287 | Phase 2 |
| high dose gt-02287 | Phase 2 |
| low dose gt-02287 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
40
Total value held
$12.0M
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 1,769,788 | $3.4M |
| vanguard capital management llc | 799,772 | $1.6M |
| jones financial companies lllp | 631,615 | $1.2M |
| susquehanna international group, llp | 469,567 | $911K |
| geode capital management, llc | 447,342 | $869K |
| jane street group, llc | 255,483 | $496K |
| vanguard fiduciary trust co | 229,979 | $446K |
| blackrock, inc. | 225,046 | $437K |
| ubs group ag | 220,489 | $428K |
| cresset asset management, llc | 160,000 | $310K |
Showing top 10 of 40 institutional holders of Gain Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Gain Therapeutics, Inc.'s pipeline?
Gain Therapeutics, Inc. (GANX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Gain Therapeutics, Inc.'s lead drug candidate?
Gain Therapeutics, Inc.'s most advanced tracked candidate is gt-02287 (Phase 2) for Parkinson Disease.
What is Gain Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Gain Therapeutics, Inc. has approximately 10.8 months of cash runway.
What is Gain Therapeutics, Inc.'s market capitalization?
Gain Therapeutics, Inc.'s market capitalization is approximately $75.9M.
Who is the CEO of Gain Therapeutics, Inc.?
Mr. Gene Mack M.B.A. is the chief executive officer of Gain Therapeutics, Inc. (GANX).
Get the full picture on Gain Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.